The findings of multiple in vivo
preclinical studies published online in Blood Advances, a Journal of the American Society of Hematology (ASH),
indicate that this therapy could potentially treat multiple cancers, including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and acute myeloid leukemia (AML).